Zigakibart Results in Sustained Proteinuria Reduction and Remission Through 124 Weeks of Treatment in Patients with IgAN (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-OR064; Pres time: Oct 23, 2026; 04:30 PM - 04:40 PM; Location: Room 501, Convention Center; P1/2 | "Conclusion Zigakibart treatment was associated with increasing and durable proteinuria remission and sustained Gd-IgA1 and IgA suppression through 124 weeks. Exploratory analyses did not suggest a clear difference in Gd-IgA1 reductions between patients with and without proteinuria remission."
Clinical • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease
|
|
Laura Kooienga; Eun Young Lee; Hamid Moradi; Johanna Sofia Justine Eliasson Vinterberg; Cong Lin; Jonathan Barratt
|